Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist (Businesswire) - Jun 29, 2022 - P2 | N=12 | EudraCT number 2017-003108-27 | Sponsor: Axalbion SA | "Results showed: Treatment with AX-8 40 mg BID compared to placebo showed a reduction in cough frequency within the first 15 minutes after treatment and lasting for more than 4 hours. This included a 44% reduction in cough frequency over two hours compared to 18% with placebo and a 35% reduction over 4 hours compared to 20% with placebo. Reduction in cough frequency was seen across patients in the study irrespective of high/low baseline cough frequency, duration of coughing, age or sex. In a pre-determined subset of patients with higher baseline throat discomfort, there was a statistically significant reduction of cough, including a 49% reduction over two hours compared to 8% with placebo and a 32% reduction over 24 hours compared to 13% with placebo...the company plans to initiate a Phase 2 study examining more frequent dosing of AX-8 in the treatment of chronic cough patients in the first quarter of 2023."
New P2 trial • P2 data • Chronic Cough • Cough • Respiratory Diseases
|